Form 8-K: Interventional Div of Bayer AG


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549
_____________________________________________________________________


FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934 
______________________________________________________________________

Date of Report (Date of earliest event reported): May 14, 2014

BOSTON SCIENTIFIC CORPORATION
(Exact name of registrant as specified in charter)


DELAWARE
1-11083
04-2695240
(State or other
(Commission
(IRS employer
jurisdiction of
file number)
identification no.)
incorporation)
 
 


One Boston Scientific Place, Natick, Massachusetts
01760-1537
(Address of principal executive offices)
(Zip code)

Registrant's telephone number, including area code:   (508) 650-8000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
 
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
 
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
 
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))






ITEM 8.01.     OTHER EVENTS.

On May 15, 2014, Boston Scientific Corporation (the Company) announced the signing of a definitive agreement to acquire the Interventional Division of Bayer AG. Closing of the transaction is subject to customary conditions and is expected to be completed in the second half of the year.

A copy of the Company's press release announcing the signing of a definitive agreement to acquire the Interventional Division of Bayer AG is included as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. Provided, however, that information on or connected to our website or the website of any third-party hyperlinked from or referenced in the Company's press release included as Exhibit 99.1 to this Current Report on Form 8-K is expressly not incorporated by reference into or intended to be filed as a part of this Current Report on Form 8-K.


ITEM 9.01.     FINANCIAL STATEMENTS AND EXHIBITS.

(d) Exhibits

Exhibit No.    Description

99.1        Press Release issued by Boston Scientific Corporation dated May 15, 2014.





SIGNATURE


Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


                    
Date: May 15, 2014
BOSTON SCIENTIFIC CORPORATION
 
 
 
 
 
 
By:
/s/ Vance R. Brown
 
 
 
Vance R. Brown
 
 
 
Vice President and Chief Corporate Counsel